Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00YPR
|
||||
| Former ID |
DCL000349
|
||||
| Drug Name |
CP-547632
|
||||
| Synonyms |
BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
OSI Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H24BrF2N5O3S
|
||||
| InChI |
InChI=1S/C20H24BrF2N5O3S/c21-12-9-14(22)13(15(23)10-12)11-31-18-16(17(24)29)19(32-27-18)26-20(30)25-5-1-2-6-28-7-3-4-8-28/h9-10H,1-8,11H2,(H2,24,29)(H2,25,26,30)
|
||||
| InChIKey |
HXHAJRMTJXHJJZ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 252003-65-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14787667, 24117408, 44847595, 56374257, 75180365, 89449533, 99032984, 103561898, 103905622, 125569056, 126665919, 128126388, 134339001, 135253187, 136946546, 137242797, 137275944, 143360656, 144115846, 152343781, 160838432, 162011598, 163098917, 163403702, 163847057, 164045828, 174528562, 180190847, 198984058, 204406860, 223366210, 223395101, 223665940, 223740279, 226547130, 242060307, 247504149, 249814520, 249860726, 250213353, 251963041, 252070376, 252160342, 252215194, 252435623, 252552606
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [536201], [536474] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
| Ref 521618 | ClinicalTrials.gov (NCT00096239) CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer. U.S. National Institutes of Health. | ||||
| Ref 542806 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7881). | ||||
| Ref 536201 | YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res. 2006 Mar 1;12(5):1630-8. | ||||
| Ref 536474 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.